Kindeva Drug Delivery has officially inaugurated its new UK headquarters at the Charnwood Campus Science Innovation and Technology Park in Loughborough. The 150,000 sq. ft. facility represents a major expansion of Kindeva’s capabilities in metered-dose inhalers (MDIs) and will play a central role in developing and testing next-generation propellants (NGPs) with a lower environmental impact.
Equipped with Chemistry, Manufacturing and Controls (CMC) strategy and regulatory expertise, the site offers integrated support across the entire drug development journey — from early-stage feasibility and analytical method development to commercial analysis.
The official launch was marked by a ribbon-cutting ceremony hosted by Kindeva CEO Milton Boyer and David Northage, Mayor of Charnwood.
Speaking at the event, Milton Boyer highlighted the site’s strategic importance: “The opening of our Loughborough Headquarters marks a significant milestone in Kindeva’s growth strategy as we continue to innovate, scale, and expand our global footprint.”
With inhalers estimated to account for 0.03% of global greenhouse gas emissions and 3% of the UK NHS carbon footprint, the facility underlines Kindeva’s ambition to lead the industry towards sustainable, low-GWP propellants while ensuring supply continuity for patients worldwide.